Action Pharma

May 2012: Action Pharma sold the phase II project AP214 targeting prevention of acute kidney injury associated with major cardiac surgery in patients at increased risk to Abbott for USD 110 million. The transaction takes up a 10th place globally among published up-front deals in the period 2007-2012.

 

Sten Verland, PhD MSc

General Partner

Mobile: +45 24 22 19 69
Email
Action Pharma Logo